Hematogenix MRD Assay Supports ZENBEXUS FDA Approval
Tinley Park, Illinois, August 19, 2026 Hematogenix has announced that its proprietary Multiple Myeloma Minimal Residual Disease (MM MRD)...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Tinley Park, Illinois, August 19, 2026 Hematogenix has announced that its proprietary Multiple Myeloma Minimal Residual Disease (MM MRD)...
Newport Beach, California, August 19, 2026 Renata Medical, a medical technology company focused on pediatric congenital heart disease (CHD),...
SAN DIEGO, June 15, 2026 Neurocrine Biosciences has presented new two-year data from its Phase 3 CAHtalyst® Pediatric study,...
NEW YORK and INDIANAPOLIS, May 14, 2026 Eli Lilly and Company and UNICEF USA announced a major global healthcare...
February 24, 2026 – Cincinnati, Ohio & Tacoma, Washington, USA Cincinnati Children’s Hospital Medical Center has announced a strategic...
